PYC, page-54

Linsanity, as you say, it hinges on VP-001 interim readouts being stellar.

Rohan has said that they are aiming to submit an IND by Q4 this year. Assuming that process goes smoothly (unlike recent IND submissions by PAR and NEU), and then allowing for the standard month wait for the FDA and ethics approval, the Phase 1/2 trial would likely commence very early next year. Rohan said that there would be a 24 month Phase 1/2 trial. So perhaps allow for an interim readout half way through which would mean some kind of data readout (mainly safety) in early 2024?

I agree with you that success in the lead program should have a positive effect on how the market perceives the other pre-clinical ocular assets.

However, with respect to PYC-001 for diabetic retinopathy, although it still appears in the pipeline on the PYC website, I noted its absence from the pipeline in the most recent company presentation (Slide 6). Also, during this presentation, I noted the comments that the company is focused on monogenic disease, which diabetic retinopathy isn’t.

Perhaps I'm reading too much into this. It’s just I’ve been around long enough to know that, while the birth of programs is always announced by companies with much fanfare, when programs die, they tend to slip away unannounced…